{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:03:03Z","timestamp":1775851383739,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Datta Meghe Institute of Higher Education and Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-026-05826-y","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:35:39Z","timestamp":1771306539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the safety, pharmacokinetics, and antiparasitic activity of DSM265, a novel antimalarial plasmodium dihydroorotate dehydrogenase inhibitor: a systematic review and meta-analysis of early clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Idris","family":"Sula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Candragupta","family":"Jihwaprani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarique Anwar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Ghaith","family":"Al Abdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid Mohammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long Chiau","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"5826_CR1","doi-asserted-by":"publisher","unstructured":"Coteron JM, et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem. 2011;54(15). https:\/\/doi.org\/10.1021\/jm200592f.","DOI":"10.1021\/jm200592f"},{"key":"5826_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30374-8","author":"S B\u00e9lard","year":"2018","unstructured":"B\u00e9lard S, Ramharter M. DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria. Lancet Infect Dis. 2018. https:\/\/doi.org\/10.1016\/S1473-3099(18)30374-8.","journal-title":"Lancet Infect Dis"},{"key":"5826_CR3","unstructured":"World malaria report 2023. Accessed: Oct. 08, 2025. [Online]. Available: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023"},{"key":"5826_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(24)00016-8","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan P. The 2023 WHO world malaria report. Lancet Microbe. 2024;5(3). https:\/\/doi.org\/10.1016\/s2666-5247(24)00016-8.","journal-title":"Lancet Microbe"},{"key":"5826_CR5","unstructured":"WHO World malaria report 2020: 20 years of global progress and challenges, World malaria report 2020: 20 years of global progress and challenges, 2020."},{"key":"5826_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21682","author":"NJ White","year":"2004","unstructured":"White NJ. Antimalarial drug resistance. J Clin Invest. 2004. https:\/\/doi.org\/10.1172\/JCI21682.","journal-title":"J Clin Invest"},{"key":"5826_CR7","doi-asserted-by":"publisher","unstructured":"Yoshida N, Yamauchi M, Morikawa R, Hombhanje F, Mita T. Increase in the proportion of Plasmodium falciparum with kelch13 C580Y mutation and decline in pfcrt and pfmdr1 mutant alleles in Papua New Guinea. Malar J. 2021;20(1). https:\/\/doi.org\/10.1186\/s12936-021-03933-6.","DOI":"10.1186\/s12936-021-03933-6"},{"key":"5826_CR8","doi-asserted-by":"publisher","unstructured":"Uwimana A, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21(8). https:\/\/doi.org\/10.1016\/S1473-3099(21)00142-0.","DOI":"10.1016\/S1473-3099(21)00142-0"},{"key":"5826_CR9","doi-asserted-by":"publisher","unstructured":"Mairet-Khedim M, et al. Clinical and in vitro resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia. Clin Infect Dis. 2021;73(3). https:\/\/doi.org\/10.1093\/cid\/ciaa628.","DOI":"10.1093\/cid\/ciaa628"},{"key":"5826_CR10","doi-asserted-by":"publisher","unstructured":"Miotto O, et al. Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathog. 2020;16(12). https:\/\/doi.org\/10.1371\/journal.ppat.1009133.","DOI":"10.1371\/journal.ppat.1009133"},{"issue":"13","key":"5826_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMOA2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab S, et al. Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea. N Engl J Med. 2023;389(13):1191\u2013202. https:\/\/doi.org\/10.1056\/NEJMOA2210956.","journal-title":"N Engl J Med"},{"key":"5826_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2016.1192462","author":"J Mischlinger","year":"2016","unstructured":"Mischlinger J, Agnandji ST, Ramharter M. Single dose treatment of malaria - current status and perspectives. Expert Rev Anti Infect Ther. 2016. https:\/\/doi.org\/10.1080\/14787210.2016.1192462.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7131","key":"5826_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/NATURE05572","volume":"446","author":"HJ Painter","year":"2007","unstructured":"Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature. 2007;446(7131):88\u201391. https:\/\/doi.org\/10.1038\/NATURE05572.","journal-title":"Nature"},{"issue":"3","key":"5826_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/187152610791163336","volume":"10","author":"MA Phillips","year":"2010","unstructured":"Phillips MA, Rathod PK. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 2010;10(3):226\u201339. https:\/\/doi.org\/10.2174\/187152610791163336.","journal-title":"Infect Disord Drug Targets"},{"key":"5826_CR15","doi-asserted-by":"publisher","unstructured":"Phillips MA, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med. 2015;7(296). https:\/\/doi.org\/10.1126\/scitranslmed.aaa6645.","DOI":"10.1126\/scitranslmed.aaa6645"},{"key":"5826_CR16","doi-asserted-by":"publisher","unstructured":"Booker ML, et al. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. J Biol Chem. 2010;285(43). https:\/\/doi.org\/10.1074\/jbc.M110.162081.","DOI":"10.1074\/jbc.M110.162081"},{"key":"5826_CR17","doi-asserted-by":"publisher","unstructured":"Phillips MA, et al. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. J Med Chem. 2008;51(12). https:\/\/doi.org\/10.1021\/jm8001026.","DOI":"10.1021\/jm8001026"},{"key":"5826_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30139-1","author":"M Sulyok","year":"2017","unstructured":"Sulyok M, et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017;17(6). https:\/\/doi.org\/10.1016\/S1473-3099(17)30139-1.","journal-title":"Lancet Infect Dis"},{"key":"5826_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30171-8","author":"JS McCarthy","year":"2017","unstructured":"McCarthy JS, et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study. Lancet Infect Dis. 2017;17(6). https:\/\/doi.org\/10.1016\/S1473-3099(17)30171-8.","journal-title":"Lancet Infect Dis"},{"key":"5826_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30309-8","author":"A Llanos-Cuentas","year":"2018","unstructured":"Llanos-Cuentas A, et al. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. Lancet Infect Dis. 2018;18(8). https:\/\/doi.org\/10.1016\/S1473-3099(18)30309-8.","journal-title":"Lancet Infect Dis"},{"key":"5826_CR21","doi-asserted-by":"publisher","unstructured":"Murphy SC, et al. A randomized trial evaluating the prophylactic activity of DSM265 against preerythrocytic plasmodium falciparum infection during controlled human malarial infection by mosquito bites and direct venous inoculation. Journal of Infectious Diseases. 2018;217(5). https:\/\/doi.org\/10.1093\/infdis\/jix613.","DOI":"10.1093\/infdis\/jix613"},{"key":"5826_CR22","doi-asserted-by":"publisher","unstructured":"McCarthy JS, et al. A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage plasmodium falciparum in healthy volunteers. Antimicrob Agents Chemother. 2020;64(1). https:\/\/doi.org\/10.1128\/AAC.01371-19.","DOI":"10.1128\/AAC.01371-19"},{"key":"5826_CR23","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, and Sterne JAC, \u201cChapter 8: Assessing risk of bias in a randomized trial [last updated October 2019], in Cochrane handbook for systematic reviews of interventions version, cochrane, 2024."},{"key":"5826_CR24","doi-asserted-by":"publisher","unstructured":"Higgins JPT, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Online). 2011;343(7829). https:\/\/doi.org\/10.1136\/bmj.d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"5826_CR25","doi-asserted-by":"publisher","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1). https:\/\/doi.org\/10.1186\/1471-2288-14-135.","DOI":"10.1186\/1471-2288-14-135"},{"key":"5826_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01837-18","author":"KA Collins","year":"2019","unstructured":"Collins KA, et al. DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with plasmodium falciparum. Antimicrob Agents Chemother. 2019;63(4). https:\/\/doi.org\/10.1128\/AAC.01837-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"5826_CR27","unstructured":"Study Results | NCT03637517 | Malaria: Relative Bioavailability and Food Effect of DSM265 | ClinicalTrials.gov. Accessed: Oct. 09, 2025. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT03637517?tab=results"},{"key":"5826_CR28","unstructured":"World malaria report 2024. Accessed: Apr. 20, 2025. [Online]. Available: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"5826_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbiopara.2010.03.019","author":"DA Baker","year":"2010","unstructured":"Baker DA. Malaria gametocytogenesis. Mol Biochem Parasitol. 2010. https:\/\/doi.org\/10.1016\/j.molbiopara.2010.03.019.","journal-title":"Mol Biochem Parasitol"},{"issue":"9","key":"5826_CR30","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1021\/ACS.JMEDCHEM.1C00173","volume":"64","author":"MJ Palmer","year":"2021","unstructured":"Palmer MJ, et al. Potent antimalarials with development potential identified by structure-guided computational optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series. J Med Chem. 2021;64(9):6085. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.1C00173.","journal-title":"J Med Chem"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05826-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:45:48Z","timestamp":1774435548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05826-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5826"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05826-y","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"142"}}